# CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Page: https://stenobird.com/podcast/hematologic-oncology-update-916423/celmods-for-multiple-myeloma-microlearning-activity-2-with-dr-paul-g-richardson
Text version: https://stenobird.com/podcast/hematologic-oncology-update-916423/celmods-for-multiple-myeloma-microlearning-activity-2-with-dr-paul-g-richardson.md
Podcast: [Hematologic Oncology Update](https://stenobird.com/podcast/hematologic-oncology-update-916423)
Published: 2026-04-10T13:00:00+00:00
Episode link: https://hematologic-oncology.captivate.fm/episode/5876-insidetheissue2025-celmodsmrdmm-micro2
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/5cfa91e0-78c1-4841-86dd-cc1394553c56.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/celmods-for-multiple-myeloma-microlearning-activity-2-with-dr-paul-g-richardson
Duration seconds: 1494

## Resource

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here .

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/celmods-for-multiple-myeloma-microlearning-activity-2-with-dr-paul-g-richardson/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hematologic-oncology-update-916423/celmods-for-multiple-myeloma-microlearning-activity-2-with-dr-paul-g-richardson.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.